Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB105 for Injection in Advanced Solid Tumors
CTR20260244Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SKB105 in Nonhematologic neoplasms, sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Mar 2026; status: active.
02
Drugs
SKB105
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20260244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260244.